Objective To study the venlafaxine combined with aripiprazole tablets and safety of treatment of somatization disorder. Methods Seventy-eight patients were randomly divided into treatment group (venlafaxine combined with aripiprazole tablets) and control group (venlafaxine alone), 39 cases each. In the ends of 2, 4, 6 weeks, the self-assessment lists of symptom (SCL-90) and adverse reaction scale (treatment emergent symptom scale, TESS) were used to evaluat the curative effect and adverse reactions. Results In the ends of 4 weeks, SCL-90 scores in the treatment group were higher than those in the control group, with statistically significant difference (P<0.05). TESS scores in the treatment group were significantly higher than those in the control group (P<0.05). 8 weeks, 12 weeks in the treatment group somatization, depression, anxiety and other factor scores improved significantly compared with the control group, the difference was statistically significant (P<0.05). Treatment group was 92.31%, higher than 79.49%, the difference was statistically significant (P<0.05); treatment group TESS score was 2.33?1.06, the control group was 2.12?0.96, the difference was not statistically significant (t=0.81). Conclusions Venlafaxine combined with aripiprazole tablets for treatment of somatization disorder is better than venlafaxine alone, and has good compliance.